Effects of extracorporeal photoimmunotherapy on soluble IL-2Ralpha, TNF-RI, and CD8 in patients with steroid-resistant acute graft-versus-host disease

Clin Immunol. 2002 Sep;104(3):248-55. doi: 10.1006/clim.2001.5240.

Abstract

Extracorporeal photoimmunotherapy (ECP) has been successfully used as adjunct treatment for steroid-resistant graft-versus-host disease (GvHD) after allogeneic stem cell transplantation. We serially investigated serum levels of soluble interleukin-2 receptor-alpha (sIL-2Ralpha), soluble tumor necrosis factor receptor I (sTNF-RI), and soluble CD8 (sCD8) in 19 patients with steroid-resistant acute GvHD before and after each ECP treatment. Highest levels of sIL-2Ralpha and sTNF-RI correlated with severe acute GvHD and infections. Despite an immediate sIL-2Ralpha and sTNF-RI decrease after each treatment cycle, a mean surge of sTNF-RI>sIL-2Ralpha during the first three ECP cycles was observed in infections. A delayed surge, i.e., after the third ECP cycle, of sIL-2Ralpha and elevated post-ECP sCD8 levels was observed in patients developing chronic GvHD. While levels of sIL-2Ralpha and sTNF-RI correlate with the severity of acute GvHD and infections during the early ECP treatment period, the recurring increase of post-ECP sCD8 possibly may serve as parameter for developing chronic GvHD.

MeSH terms

  • Acute Disease
  • Adult
  • Antigens, CD / blood
  • Bone Marrow Transplantation / adverse effects
  • CD8 Antigens / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / therapy*
  • Humans
  • Immunotherapy*
  • Interleukin-2 Receptor alpha Subunit
  • Male
  • Middle Aged
  • Phototherapy*
  • Receptors, Interleukin / blood
  • Receptors, Tumor Necrosis Factor / blood
  • Receptors, Tumor Necrosis Factor, Type I
  • Stem Cell Transplantation / adverse effects

Substances

  • Antigens, CD
  • CD8 Antigens
  • IL2RA protein, human
  • Interleukin-2 Receptor alpha Subunit
  • Receptors, Interleukin
  • Receptors, Tumor Necrosis Factor
  • Receptors, Tumor Necrosis Factor, Type I